title: Immunohistochemical detection of CD34, E-cadherin, claudin-1, glucose transporter 1, laminin, and protein gene product 9.5 in 28 canine and 8 feline meningiomas.
abstract: The variation in histologic pattern of meningiomas can make their diagnosis challenging. The immunohistochemical profile of 28 canine and 8 feline meningiomas was examined. Tumor types included anaplastic (6 dogs), angiomatoid (1 cat), fibroblastic (3 dogs, 1 cat), meningothelial (1 dog), microcystic (2 dogs), myxoid (3 dogs), psammomatous (4 cats), and transitional (13 dogs, 2 cats). The authors compared the expression of novel markers (CD34, E-cadherin, claudin-1, glucose transporter 1 [GLUT-1], laminin, and protein gene product [PGP] 9.5) with published markers (cytokeratins, glial fibrillary acidic protein [GFAP], progesterone receptor, S100, and vimentin). Neoplastic cells were immunohistochemically positive for vimentin in 100% of the meningiomas; CD34, 94%; GLUT-1, 86%; E-cadherin, 81%; S100, 75%; laminin, 72%; claudin-1, 60%; PGP 9.5, 55%; progesterone receptor, 44%; pancytokeratins, 39%; cytokeratins 8/18, 17%, and GFAP in 9%. Ki67 index did not correlate well with mitotic index. Based on these results and those in the human literature, immunohistochemistry for vimentin, CD34, and E-cadherin is proposed to support a diagnosis of meningioma. Immunohistochemistry for claudin-1, albeit of only moderate to low sensitivity in canine and feline meningiomas, may help to distinguish meningioma from some mesenchymal neoplasms involving the brain and associated structures, such as schwannomas, which in humans express claudin-1 poorly or not at all. Further studies with CD34, E-cadherin, and claudin-1 in canine and feline tumors that may mimic meningiomas are needed to determine the adequacy of this approach.
authors.affiliation: Animal Disease Diagnostic Laboratory, Purdue University, 406 South University, West Lafayette, IN 47907, USA. ramosja@purdue.edu
authors.forename: J A
authors.initials: JA
authors.lastname: Ramos-Vara
authors.forename: M A
authors.initials: MA
authors.lastname: Miller
authors.forename: E
authors.initials: E
authors.lastname: Gilbreath
authors.forename: J S
authors.initials: JS
authors.lastname: Patterson
mesh_terms: D000818:Animals; D018952:Antigens, CD34 / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000378:metabolism; D015820:Cadherins / Q000378:metabolism; D002371:Cat Diseases / Q000175:diagnosis / Q000378:metabolism / Q000473:pathology*; D002415:Cats; D016543:Central Nervous System Neoplasms / Q000175:diagnosis / Q000378:metabolism / Q000473:pathology / Q000662:veterinary*; D062445:Claudin-1; D004283:Dog Diseases / Q000175:diagnosis / Q000378:metabolism / Q000473:pathology*; D004285:Dogs; D005260:Female; D051272:Glucose Transporter Type 1 / Q000378:metabolism; D007150:Immunohistochemistry / Q000662:veterinary; D007797:Laminin / Q000378:metabolism; D008297:Male; D008565:Membrane Proteins / Q000378:metabolism; D008579:Meningioma / Q000175:diagnosis / Q000473:pathology / Q000662:veterinary*
chemical_list: D018952:Antigens, CD34; D014408:Biomarkers, Tumor; C568108:CLDN1 protein, human; D015820:Cadherins; D062445:Claudin-1; D051272:Glucose Transporter Type 1; D007797:Laminin; D008565:Membrane Proteins